📣ESMO #ClinicalPracticeGuideline Express Update on #EpithelialOvarianCancer:
- Rucaparib: 1st-line PARPi maintenance option
- MIRV: for recurrent FRα-high #OvarianCancer after 1-3 prior therapies & PFI <6 months

🔗 https://ow.ly/J06u50Y4HT8

#GYNOnc #Oncology #ESMOGuidelines

#LamaBerjawi is presenting our results about #ferroptosis, #senescence and #epithelialovariancancer at #EACR2025 @udc.gal @cicaudc.bsky.social #INIBIC